The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Review: Blood pressure and dementia — a comprehensive review
Open accessAbstract
Alzheimer's disease (AD) and vascular dementia (VaD) are important causes of cognitive decline in the elderly. As a result of an ageing population worldwide, the incidence of dementia is expected to rise exponentially over the coming decades. Vascular risk factors are implicated in the pathogenesis of both AD and VaD. Hypertension in midlife is particularly associated with an increased risk of developing dementia. One might hope the treatment of high blood pressure in midlife would reduce the risk of developing dementia, as it does the risk of stroke. Divergent results have been reported in studies examining this effect, with the evidence suggesting that certain antihypertensives confer benefits beyond others. This implies that certain drugs may have neuroprotective properties separate to their blood pressure lowering capabilities. Recent trials have added to our understanding of these relationships.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Zola-Morgan, S., Squire, L., & Amaral, D. (1986) · The Journal of Neuroscience · doi:10.1523/jneurosci.06-10-02950.1986 · Cited by 1,997
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726 · cited 2×
“Only one study [Skoog et al. 1996] described an association between both elevated systolic and diastolic blood pressure and a subsequent diagnosis of AD or dementia.”
BackgroundKivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
Midlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207 · cited 1×
“As with hypertension in midlife, several studies have described an association between atherosclerosis [Hofman et al. 1997], high cholesterol, diabetes mellitus, obesity [Kivipelto et al. 2002; Peila et al. 2002; Romas et al. 1999; Chandra and Pandav 1998] and the incidence of AD.”
BackgroundMidlife blood pressure and dementia: the Honolulu–Asia aging study☆
Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., & Havlik, R. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00096-8 · Cited by 1,008
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiyama, K., Kawano, H., Ueda, K., et al. (1995) · Neurology · doi:10.1212/wnl.45.6.1161 · Cited by 829
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770 · cited 2×
“Hypertension in the Very Elderly Trial – cognitive function assessment (HYVET-COG) (Diuretic þ/ ACE inhibitor) The Hypertension in the Very Elderly Trial (HYVET) was designed to assess the risks and benefits of treatment of hypertension in elderly patients and included a cognitive assessment, the HYVET-COG [Peters et…”
MethodHypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression
Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Huang, L. E., & Song, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606298103 · Cited by 605 · cited 2×
“Recently evidence has emerged that hypoxia-induced factors (HIF) may potentiate these amyloidogenic mechanisms, which may ultimately result in AD expression [Zhang et al. 2007; Sun et al. 2006].”
BackgroundPetrovitch, H., White, L. R., Izmirilian, G., Ross, G. W., Havlik, R. J., Markesbery, W., Nelson, J., Davis, D. G., Hardman, J., Foley, D. J., et al. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00106-8 · Cited by 468 · cited 1×
“The autopsy follow-up of 243 participants [Petrovitch et al. 2000] demonstrated that elevated SBP in midlife was associated with vasculopathic changes, a lower brain weight and greater numbers of neuritic ( -amyloid) plaques in both the neocortex and the hippocampus.”
BackgroundDufouil, C., Chalmers, J., Coskun, O., Besançon, V., Bousser, M.-G., Guillon, P., MacMahon, S., Mazoyer, B., Neal, B., Woodward, M., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.501163 · Cited by 461 · cited 1×
“The progression of white matter intensities on MRI, implicated in the pathogenesis of both AD and VaD, is also modified by ACE inhibitors [Dufouil et al. 2005]. b-blockers There have been several studies regarding the impact of -blockers on cognitive function in patients with [Gliebus and Lippa…”
BackgroundZhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F.-F., Xu, H., & Zhang, Y.-W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608856200 · Cited by 436
Dementia after ischemic stroke: A population-based study in Rochester, Minnesota (1960-1984)
Kokmen, E., Whisnant, J. P., O'Fallon, W. M., Chu, C.-P., & Beard, C. M. (1996) · Neurology · doi:10.1212/wnl.46.1.154 · Cited by 434
Yamada, M., Kasagi, F., Sasaki, H., Masunari, N., Mimori, Y., & Suzuki, G. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51117.x · Cited by 255
Antihypertensive drugs and incidence of dementia: the Rotterdam Study
in’t Veld, B. A., Ruitenberg, A., Hofman, A., Stricker, B. H. C., & Breteler, M. M. B. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00241-4 · Cited by 254 · cited 1×
“…ic a l M a n u a l o f M e n ta l D is o rd e rs , 3 rd e d it io n (r e vi se d ); B M I, b o d y m a ss in d e x; A H R , a d ju st e d h a za rd ra ti o ; C I, co n fi d e n ce in te rv a l. http://tan.sagepub.com 249 between antihypertensive therapy and VaD but not AD [In’t Veld et al. 2001].”
BackgroundMorris, M. C., Scherr, P. A., Hebert, L. E., Glynn, R. J., Bennett, D. A., & Evans, D. A. (2001) · Archives of Neurology · doi:10.1001/archneur.58.10.1640 · Cited by 217
Reducing the Risk of Dementia: Efficacy of Long-Term Treatment of Hypertension
Peila, R., White, L. R., Masaki, K., Petrovitch, H., & Launer, L. J. (2006) · Stroke · doi:10.1161/01.str.0000217653.01615.93 · Cited by 181 · cited 2×
“The Honolulu-Asia Ageing Study (HAAS) was conducted on a sample of Asian American men between 1965 and 1995 [Launer et al. 2000].”
BackgroundCalcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging
Yasar, S., Corrada, M., Brookmeyer, R., & Kawas, C. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.009 · Cited by 116
Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3 · cited 9×
“In contrast, ACE inhibitors were the only AH drug class potentially associated with a slight increased risk for AD (adjusted hazard ratio 1.13), in the Cache County cohort [Khachaturian et al. 2006].”
BackgroundMethodResultInfluential
Cited by
The projected effect of risk factor reduction on Alzheimer's disease prevalence
Barnes, D. E., & Yaffe, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70072-2 · Cited by 2,666
Zhou, B., Perel, P., Mensah, G. A., & Ezzati, M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00559-8 · Cited by 1,521
Bennett, J. E., Stevens, G. A., Mathers, C. D., Bonita, R., Rehm, J., Kruk, M. E., Riley, L. M., Dain, K., Kengne, A. P., Chalkidou, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31992-5 · Cited by 1,336
2010 Alzheimer's disease facts and figures
Alzheimer's Association (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.01.009 · Cited by 684
Hypertension-induced cognitive impairment: From pathophysiology to public health
Ungvari, Z., Toth, P., Tarantini, S., Prodan, C. I., Sorond, F., Merkely, B., & Csiszar, A. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00430-6 · Cited by 544
Metadata
- Authors
- Kennelly, S. P., Lawlor, B. A., & Kenny, R. A.
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2009-05-28
- Volume
- 2
- Issue
- 4
- Pages
- 241-260
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- OpenAlex
- W1453510387
- Cited by
- 159
- References
- 23
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.